Home > News > Kereos' Collaborators Present on Targeted Therapies
November 15th, 2005
Kereos' Collaborators Present on Targeted Therapies
Abstract:
Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, announced today that the company's collaborators at Washington University School of Medicine will be presenting preclinical data on two therapeutic candidates at the American Heart Association (AHA) Scientific Sessions this week. These agents are the first cardiovascular-targeted therapeutics in Kereos' pipeline of ligand-targeted emulsions, and represent two of the first applications of nanotechnology to treating cardiovascular disease.
Source:
prnewswire
Related News Press |
Possible Futures
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
With VECSELs towards the quantum internet Fraunhofer: IAF achieves record output power with VECSEL for quantum frequency converters April 5th, 2024
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||